Eradication of Helicobacter pylori, starting with rational use of antibiotics

Abstract

Abstract: Antibiotic resistance is the primary cause of treatment failure on Helicobacter pylori infection. Due to a large number of clinicians involved in the treatment of Helicobacter pylori infection in China, the irregular treatment, and the overuse of antibiotics, the resistance rate of Helicobacter pylori to various antibiotics has gradually increased, leading to the decline of successful treatment of Helicobacter pylori infection. In order to improve the eradication rate of Helicobacter pylori and combat antibiotic resistance, this review summarizes the pharmacological mechanism of seven antibiotics which are currently used for Helicobacter pylori treatment. In addition, this review also evaluates the antibiotic resistance genes associated with each of the recommended drugs to help clinicians gain a deeper understanding of the drug choices. Lastly, in regions where antibiotic resistance is common, we encourage clinical doctors to provide antibiotic susceptibility guided treatment to improve treatment success rate, reduce the emergence of resistant strains, shorten the treatment process, avoid the waste of medical resources, improve the Helicobacter pylori eradication rate, reduce the recurrence of peptic ulcer, delay the process of MALT lymphoma, prevent gastric cancer, and benefit the patients.

Key words: Helicobacter pylori, Antibiotics, Drug resistance

Ren Xiaoying, Li Xuehong, Zhang Shuzhen, Wang Xiangyu, Sylvia Young, Barry Marshall, Alfred Chin Yen Tay. Eradication of Helicobacter pylori, starting with rational use of antibiotics[J]. Electronic Journal of Emerging Infectious Diseases, 2020, 5(1): 38-42.

References

[1] Marshall B, Warren JR.Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J]. Lancet,1984,323(8390):1311-1315.
[2] International Agency for Research on Cancer. Schistosomes, liver flukes and helicobacter pylori[J]. Int J Cancer, 1994, 60(5):587-589.
[3] 叶任高, 陆再英. 内科学[M]. 北京: 人民卫生出版社 2004.
[4] 曾化松, 王艳琳. 抗生素滥用的现状及应对策略[J]. 中国卫生事业管理, 2012,29(5):341-343.
[5] 肖永红, 侯芳, 王进,等. 抗菌药物不良反应的社会与经济后果调查[J]. 中国卫生经济, 2010, 29(5):94-96.
[6] 朱静, 徐彦贵, 高仲阳. 克拉霉素的药理特性及应用[J]. 中国医院药学杂志, 2001,21(9):551-553.
[7] 成虹, 胡伏莲, 谢勇,等. 中国幽门螺杆菌耐药状况以及耐药对治疗的影响—全国多中心临床研究[J]. 胃肠病学 2007,12(9):525-530.
[8] Marshall BJ, Tay AC-Y.胃癌预防主要策略:根除幽门螺杆菌[J]. 新发传染病电子杂志, 2018,3(4):7-8.
[9] 胡伏莲. 幽门螺杆菌耐药性及治疗失败原因分析[J]. 中国消化内镜, 2009(3):1-8.
[10] Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance[J]. World J Gastroenterol: WJG 2014,20:9912.
[11] Goodwin A, Kersulyte D, Sisson G, et al.Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase[J]. Mol Microbiol 1998,28(2):383-393.
[12] Jorgensen MA, Manos J, Mendz GL, et al.The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction?[J]. J Ant Chem, 1998,41:67-75.
[13] Kwon DH, El-Zaatari FA, Kato M, et al.Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori[J]. Ant Agent Chemr, 2000,44(8):2133-2142.
[14] Rimbara E, Noguchi N, Kawai T, et al.Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB[J]. Helicobacter, 2012,17(1):36-42.
[15] 胡伏莲, 胡品津, 刘文忠,等. 第三次全国幽门螺杆菌感染若干问题共识报告[J]. 临床药物治疗杂志, 2008, 9(3):13-18.
[16] Dailidiene D, Bertoli M T, Miciuleviciene J, et al.Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci[J]. Ant Chem, 2002, 46(12):3940-3946.
[17] Trieber CA, Taylor DE.Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline[J]. J Bacteriol , 2002, 184(8):2131-2140.
[18] 赵海敏, 王伯军. 利福平对幽门螺杆菌体内外抗菌作用的评[J]. 现代实用医学, 2015, 27(1):21-22.
[19] Brogden RN, Fitton A.Rifabutin[J]. Drugs, 1994, 47(6):983-1009.
[20] Rossi R, Jabes D, Della Bruna C.In vitro activity of rifabutin, a potential antibiotic in the therapy of Helicobacter pylori[S].In: Abstract Book of the 6th International Congress for Infectious Diseases, Prague(Czech Republic). 1994.
[21] Heep M, Beck D, Bayerdörffer E, et al.Rifampin and Rifabutin resistance mechanism in Helicobacter pylori[J]. Ant Agent Chem, 1999,43(5):1497-1499.
[22] Perri F, Festa V, Merla A, et al.Amoxicillin-tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection[J]. Helicobacter, 2002,7(2):99-104.
[23] Akyildiz M, Akay S, Musoglu A, et al.The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication[J]. Eur J Intern Med, 2009,20(1):53-57.
[24] 温晋锋, 王伯军, 丁勇, 等. 含多西环素的四联方案根除幽门螺杆菌的疗效[J]. 中国临床保健杂志, 2014,17(3):235-238.
[25] 张灵云, 蓝宇, 宋志强. 半合成四环素在幽门螺杆菌根除中的应用[J]. 中国抗生素杂志, 2016,41(9):647-652.
[26] Okamoto T, Yoshiyama H, Nakazawa T, et al.A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori[J]. J Ant Chem, 2002,50(12):849-856.
[27] Sisson G, Goodwin A, Raudonikiene A, et al.Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori[J]. Ant Agent Chem, 2002,46:2116-2123.
[28] 尤丽财, 彭孝纬, YOULicai, 等. 幽门螺杆菌对呋喃唑酮的耐药状况及耐药机制的研究[J]. 胃肠病学和肝病学杂志, 2009, 18(5):423-426.
[29] Kwon DH, Lee M, Kim JJ, et al.Furazolidone-and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance[J]. Ant Agent Chem, 2001,45:306-308.
[30] Hu Y, Zhu Y, Lu N.Primary antibiotic resistance of Helicobacter pylori in China[J]. Dig Dis Sci, 2017,62(21):1146-1154.
[31] 刘文忠, 谢勇, 陆红,等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6):346-360.
[32] 于学敏, 冯辉, 杨慧荣,等. 铋盐类药物的研发及在Hp根除治疗中的应用[J]. 中国药事, 2012,26:394-403.
[33] 胡奕, 吕农华. 我国幽门螺杆菌感染防治中面临的问题与对策[J]. 现代消化及介入诊疗, 2019, 24(3):8-11.
[34] 中华医学会儿科学分会消化学组,《中华儿科杂志》编辑委员会. 儿童幽门螺杆菌感染诊治专家共识[J]. 中华儿科杂志, 2015, 53(7):496-498.
[35] Razavi A, Bagheri N, Azadegan-Dehkordi F, et al.Comparative immune response in children and adults with H. pylori infection[J]. J Immunol Res, 2015,2015(1):1-6.
[36] Vanderpas J, Bontems P, Deyi VM, et al.Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates[J]. Epi Infect, 2014,142(13):767-775.
[37] Neunert C, Lim W, Crowther M, et al.The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011, 117(16):4190-4207.